Industry
- Aerospace & Defense 12
- Analytics 10
- Apparel 6
- Bank 16
- Beverages / Food 4
- Car Manufacturing 7
- Chemicals 3
- Communication Services 3
- Consulting 3
- Consumer Defensive 10
- Consumer Discretionary 18
- Credit Services 10
- Cybersecurity 3
- Data 6
- Energy 12
- Entertainment 4
- Exchanges 5
- Farm & Heavy Construction Machinery 2
- Financial 46
- Food Processing 1
- Grocery Store 5
- Hardware 18
- Healthcare 6
- Holding Company 5
- Home Improvement 2
- Industrial 37
- Information Technology 16
- Insurance 15
- Investment Banking 5
- Logistics 9
- Luxury 6
- Market Infrastructure 9
- Materials 6
- Mining 3
- Oil & Gas 12
- Payment 5
- Personal Care & Beauty 1
- Pharmaceuticals 4
- Railroad 5
- Ratings 6
- Real Estate 5
- Restaurants 4
- Retail 16
- Semi-Conductors 17
- Software 17
- Technology 39
- Telecommunications 11
- Trade Distributors 4
- Utilities 6
- Waste Management 4
Johnson & Johnson (JNJ) investment Quality Rating (A)
View the (A) forensic audit of Johnson & Johnson (JNJ). Old York Financial analyzes $26.9B Owner Earnings, the Shockwave acquisition, and the impact of the $1.5B talc verdict. See why JNJ is the "Healthcare Sovereign" of 2026.
Novartis AG (NVS) investment Quality Rating (A)
Read the (A) forensic audit of Novartis (NVS). Old York Financial analyzes $23.1B Owner Earnings, the 40% Core Margin milestone, and the 2026 Entresto patent cliff strategy. See why Novartis is the "Pure-Play" sovereign of 2026.
AbbVie Inc. (ABBV) investment Quality Rating (A)
Access the (A) forensic audit of AbbVie (ABBV). Old York Financial analyzes $25.9B Owner Earnings, the post-Humira recovery, and the Skyrizi/Rinvoq growth engine. See why AbbVie is the "Cash Flow Utility" of 2026.
Eli Lilly and Company (LLY) investment Quality Rating (AA)
Explore the (AA) forensic audit of Eli Lilly (LLY). Old York Financial analyzes $14.4B Owner Earnings, the $55B manufacturing moat, and the "Metabolic Sovereign" growth strategy for 2026.